These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 37732622

  • 1. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
    Jin H, Zhu J, Xuan R, Zhou Y, Xue B, Yang D, Gao J, Zang Y, Xu L.
    Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
    [Abstract] [Full Text] [Related]

  • 2. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways.
    Zhou S, Dai Z, Wang L, Gao X, Yang L, Wang Z, Wang Q, Liu Z.
    J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497
    [Abstract] [Full Text] [Related]

  • 3. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
    Xu L, Shen M, Chen X, Zhu R, Yang DR, Tsai Y, Keng PC, Chen Y, Lee SO.
    Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
    Xu L, Chen X, Shen M, Yang DR, Fang L, Weng G, Tsai Y, Keng PC, Chen Y, Lee SO.
    Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
    [Abstract] [Full Text] [Related]

  • 5. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
    Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N.
    Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
    [Abstract] [Full Text] [Related]

  • 6. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
    Zhang L, Xu LJ, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX.
    Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
    [Abstract] [Full Text] [Related]

  • 7. In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells.
    Xu L, Shen M, Chen X, Yang DR, Tsai Y, Keng PC, Lee SO, Chen Y.
    Exp Cell Res; 2018 Mar 01; 364(1):113-123. PubMed ID: 29408565
    [Abstract] [Full Text] [Related]

  • 8. Combined inhibition of JAK1,2/Stat3‑PD‑L1 signaling pathway suppresses the immune escape of castration‑resistant prostate cancer to NK cells in hypoxia.
    Xu LJ, Ma Q, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR, Shan YX.
    Mol Med Rep; 2018 Jun 01; 17(6):8111-8120. PubMed ID: 29693186
    [Abstract] [Full Text] [Related]

  • 9. Sophocarpine inhibits tumor progression by antagonizing the PI3K/AKT/mTOR signaling pathway in castration-resistant prostate cancer.
    Weng M, Shi C, Han H, Zhu H, Xiao Y, Guo H, Yu Z, Wu C.
    PeerJ; 2022 Jun 01; 10():e14042. PubMed ID: 36132221
    [Abstract] [Full Text] [Related]

  • 10. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
    Kosaka T, Miyajima A, Shirotake S, Kikuchi E, Oya M.
    Prostate; 2011 Oct 01; 71(14):1510-7. PubMed ID: 21321983
    [Abstract] [Full Text] [Related]

  • 11. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H, Kosaka T, Oya M.
    Cancer Sci; 2018 Sep 01; 109(9):2937-2945. PubMed ID: 29989268
    [Abstract] [Full Text] [Related]

  • 12. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, Kamba T, Imamura T.
    Prostate; 2021 Feb 01; 81(3):147-156. PubMed ID: 33368414
    [Abstract] [Full Text] [Related]

  • 13. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D.
    Oncotarget; 2015 Dec 08; 6(39):41976-87. PubMed ID: 26506516
    [Abstract] [Full Text] [Related]

  • 14. Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers.
    Zhang A, Lau NA, Wong A, Brown LG, Coleman IM, De Sarkar N, Li D, DeLucia DC, Labrecque MP, Nguyen HM, Conner JL, Dumpit RF, True LD, Lin DW, Corey E, Alumkal JJ, Nelson PS, Morrissey C, Lee JK.
    Cancer Res Commun; 2023 Nov 20; 3(11):2358-2374. PubMed ID: 37823778
    [Abstract] [Full Text] [Related]

  • 15. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB, Hwang C.
    Prostate; 2019 Aug 20; 79(11):1347-1359. PubMed ID: 31228231
    [Abstract] [Full Text] [Related]

  • 16. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S, Gui B, Wu J, Liu XS, Kibel AS, Jia L.
    Mol Cancer Res; 2019 Jan 20; 17(1):263-276. PubMed ID: 30224544
    [Abstract] [Full Text] [Related]

  • 17. Determining the prognostic significance of IKKα in prostate cancer.
    Montes M, MacKenzie L, McAllister MJ, Roseweir A, McCall P, Hatziieremia S, Underwood MA, Boyd M, Paul A, Plevin R, MacKay SP, Edwards J.
    Prostate; 2020 Oct 20; 80(14):1188-1202. PubMed ID: 33258506
    [Abstract] [Full Text] [Related]

  • 18. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
    Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, Zeng H, Zhang N, Du W, Chen C, Huang JA.
    Int J Clin Oncol; 2017 Dec 20; 22(6):1026-1033. PubMed ID: 28748356
    [Abstract] [Full Text] [Related]

  • 19. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, Kearsley J, Li Y.
    Int J Biochem Cell Biol; 2013 Dec 20; 45(12):2736-48. PubMed ID: 24076216
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M, Gao S, Zhang L, Liu B, Li J, Wang Z, Zhang W.
    Prostate; 2020 Jul 20; 80(10):742-752. PubMed ID: 32449811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.